黄亮，准聘副教授，主任医师，博士研究生导师。任中国医学科学院血液病医院临床研究平台负责人、病区主任、PI。获科技部重点研发专项课题、“863计划”青年科学家专题、国家自然科学基金面上项目、中国医学科学院医学与健康科技创新工程项目等资助。曾入选首期“楚天英才·湖北省青年拔尖人才计划”。 老虎机游戏引进人才，2024年加入老虎机游戏。曾在华中科技大学同济医学院附属同济医院任副教授、主任医师，并担任血液内科副主任等职务。

长期从事淋巴系统肿瘤的精准诊疗研究。系统揭示了淋巴肿瘤患者CAR-T治疗后长期生存的限制因素及机制，并针对性提出了创新的临床解决方案。开展了国际上首个CAR-T细胞“鸡尾酒疗法”，显著降低靶点阴性复发率；推进CAR-T联合自体造血干细胞移植，使高危患者长期生存率提升约60%；率先发现并防治了CAR-T治疗后的乙肝和EB病毒再激活，降低了治疗相关死亡率。以第一或通讯作者（含共同）在 Blood、Cell Res等权威期刊上发表SCI论文30余篇。

老虎机游戏

(1) Cheng J^#, Hu X^#, Dai Z^#, Zeng Y, Jin J, Mu W, Wei Q, Jia X, Liu J, Xie M, Luo Q, Hu G, Wang G, Zhu X, Zhou J, Xiao M, Wang J^*, Tan T^*, Huang L^*. Targeting intracellular LMP2 with costimulatory signal-armed antibody-like TCR T cells. JCI Insight. 2025 May 22;10(10):e178572.

(2) Cheng Y^#, Zhang J^#, Mu W^#, Ye S, Cheng J, Zhu L, Wang G, Cao Y, Li D, Hu G^*, Huang L^*, Wang J^*, Zhou J. Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Mol Ther. 2025 Apr 2;33(4):1535-1551.

(3) Li Z^#*, Zhao L^#, Zhang Y, Zhu L, Mu W, Ge T, Jin J, Tan J, Cheng J, Wang J, Wang N, Zhou X, Chen L, Chang Z, Liu C, Bian Z, Liu B^*, Ye L^*, Lan Y^*, Huang L^*, Zhou J. Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients. Cell Rep. 2023 Oct 31;42(10):113263.

(4) Li H^#, Yang X, Wang Z, She W, Liu Y^*, Huang L^*, Jiang P^*. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming. ACS Nano. 2023 Jun 27;17(12):11749-11763.

(5) Tang Y^#, Xu Q^#, Luo H^#, Yan X, Wang G, Hu L, Jin J, Witte DP, Marsh RA, Huang L^*, Huang G^*, Zhou J^*. Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis. J Allergy Clin Immunol. 2022 Nov;150(5):1154-1167.

(6) Wei J^#, Xiao M^#, Mao Z^#, Wang N, Cao Y, Xiao Y, Meng F, Sun W, Wang Y, Yang X, Chen L, Zhang Y, Zhu H, Zhang S, Zhang T, Zhou J^*, Huang L^*. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduct Target Ther. 2022 Apr 11;7(1):101.

(7) Cao W^#, Wei J^#, Wang N, Xu H, Xiao M, Huang L, Cao Y, Li C, Xiao Y, Gu C, Zhang S, Li D, Zhang Y, Zhang T, Zhou J^*, Huang L^*. Entecavir Prophylaxis for Hepatitis B Virus Reactivation in Patients with CAR T-cell Therapy. Blood. 2020 Jul 23;136(4):516-519.

(8) Wang N^#, Hu X^#, Cao W, Li C, Xiao Y, Cao Y, Gu C, Zhang S, Chen L, Cheng J, Wang G, Zhou X, Zheng M, Mao X, Jiang L, Wang D, Wang Q, Lou Y, Cai H, Yan D, Zhang Y, Zhang T, Zhou J^*, Huang L^*. Efficacy and Safety of CAR19/22 T-cell Cocktail Therapy in Patients with Refractory/Relapsed B-Cell Malignancies. Blood. 2020 Jan 2;135(1):17-27.

(9) Huang L^#, Liu D^#, Wang N^#, Ling S^#, Tang Y^#, Wu J, Hao L, Luo H, Hu X, Sheng L, Zhu L, Wang D, Luo Y, Shang Z, Xiao M, Mao X, Zhou K, Cao L, Dong L, Zheng X, Sui P, He J, Mo S, Yan J, Ao Q, Qiu L, Zhou H, Liu Q, Zhang H, Li J, Jin J, Fu L, Zhao W, Chen J, Du X, Qing G, Liu H, Liu X, Huang G, Ma D, Zhou J^*, Wang QF^*. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018 Feb;28(2):172-186.

(10) Tang YT^#, Wang D^#, Luo H^#, Xiao M, Zhou HS, Liu D, Ling SP, Wang N, Hu XL, Luo Y, Mao X, Ao QL, Huang J, Zhang W, Sheng LS, Zhu LJ, Shang Z, Gao LL, Zhang PL, Zhou M, Zhou KG, Qiu LG, Liu QF, Zhang HY, Li JY, Jin J, Fu L, Zhao WL, Chen JP, Du X, Huang G, Wang QF, Zhou JF^*, Huang L^*. Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer J. 2017 Dec 21;7(12):660.